BEIGF
BeOne Medicines AG
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Neutral
-5/100
Last price
21.95
■ 0.00 (0.00%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
21.95
Day high
23.75
Day low
23.75
Volume
100
Market cap
$32.46B
P/E (TTM)
51.04
52W range
15.95 – 25.30
Trailing performance
Returnvs SPY
1W
0.00%
-1.9%
1M
0.00%
-1.5%
3M
0.00%
-3.4%
6M
-7.60%
-22.6%
YTD
-13.24%
-27.2%
1Y
+37.59%
+21.9%
3Y
+58.00%
-23.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BEIGF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
203.29M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Dec 31, 25 | BRANDICOURT OLIVIER Independent Non-Executive Director |
— | 16.34K | — | Direct |
| Dec 31, 25 | Dugan (Margaret) Independent Non-Executive Director |
— | 16.34K | — | Direct |
| Dec 31, 25 | Goller (Michael J.) Independent Non-Executive Director |
— | 16.34K | — | Direct |
| Dec 31, 25 | Hooper (Anthony C) Independent Non-Executive Director |
— | 12.92K | — | Direct |
| Dec 31, 25 | Krishana (Ranjeev) Independent Non-Executive Director |
— | 16.34K | — | Direct |
| Dec 31, 25 | Oyler (John Victor) Chief Executive Officer |
— | 3.07M | — | Direct |
| Dec 31, 25 | Riva (Alessandro) Independent Non-Executive Director |
— | 16.34K | — | Direct |
| Dec 31, 25 | Sanders (Corazon Corsee D) Independent Non-Executive Director |
— | 16.34K | — | Direct |
| Dec 31, 25 | Wang (Xiaodong) Director (Non-Executive) |
— | 677.56K | — | Direct |
| Dec 31, 25 | Yi (Qingqing) Independent Non-Executive Director |
— | 13.27K | — | Direct |
| Dec 31, 24 | Krishana (Ranjeev) Independent Non-Executive Director |
— | 12.92K | — | Direct |
| Dec 31, 24 | Oyler (John Victor) Chief Executive Officer |
— | 612.04K | — | Direct |
| Dec 31, 24 | Riva (Alessandro) Independent Non-Executive Director |
— | 12.92K | — | Direct |
| Dec 31, 24 | Sanders (Corazon Corsee D) Independent Non-Executive Director |
— | 12.92K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BRANDICOURT OLIVIER |
Independent Non-Executive Director | 16.34K | Other |
Dugan (Margaret) |
Independent Non-Executive Director | 45.95K | Other |
Goller (Michael J.) |
Independent Non-Executive Director | 63.04K | Other |
Hooper (Anthony C) |
Independent Non-Executive Director | 37.41K | Other |
Krishana (Ranjeev) |
Independent Non-Executive Director | 63.04K | Other |
Oyler (John Victor) |
Chief Executive Officer | 24.73M | Other |
Riva (Alessandro) |
Independent Non-Executive Director | 45.95K | Other |
Sanders (Corazon Corsee D) |
Independent Non-Executive Director | 46.24K | Other |
Wang (Xiaodong) |
Director (Non-Executive) | 5.36M | Other |
Yi (Qingqing) |
Independent Non-Executive Director | 16.34K | Other |
Fundamentals
Market cap$32.46B
Enterprise value$29.39B
Revenue (TTM)$6.13B
Gross profit$5.45B
EBITDA$1.07B
Net income$655.71M
EPS (TTM)$0.43
Free cash flow$879.02M
Total cash$5.10B
Total debt$2.05B
Book value / share$3.52
Shares outstanding1.36B
Float1.05B
Short % of float—
Dividend yield0.00%
Beta (5Y)0.61
Valuation & profitability ratios
Trailing P/E51.04
Forward P/E—
PEG ratio0.60
Price / sales—
Price / book6.23
EV / revenue4.80
EV / EBITDA27.43
Gross margin88.89%
Operating margin19.06%
Profit margin10.70%
Return on equity14.66%
Return on assets7.46%
Debt / equity39.61
Current ratio3.41
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $5.34B | $3.81B | $2.46B | $1.42B | +40.2% |
| Operating revenue | $6.79B | $4.81B | $2.98B | $1.59B | +41.1% |
| Cost of revenue | $668.54M | $594.09M | $379.92M | $286.48M | +12.5% |
| Gross profit | $4.67B | $3.22B | $2.08B | $1.13B | +45.3% |
| Research & development | $2.15B | $1.95B | $1.78B | $1.64B | +9.9% |
| Selling, general & admin | $2.08B | $1.83B | $1.51B | $1.28B | +13.7% |
| Total operating expense | $4.23B | $3.78B | $3.29B | $2.92B | +11.7% |
| Operating income | $447.14M | -$568.20M | -$1.21B | -$1.79B | +178.7% |
| Net interest income | $12.27M | $47.84M | $74.01M | $52.48M | -74.3% |
| Pre-tax income | $416.85M | -$533.00M | -$825.84M | -$1.96B | +178.2% |
| Tax provision | $129.92M | $111.78M | $55.87M | $42.78M | +16.2% |
| Net income | $286.93M | -$644.79M | -$881.71M | -$2.00B | +144.5% |
| Net income to common | $286.93M | -$644.79M | -$881.71M | -$2.00B | +144.5% |
| Basic EPS | 0.20 | -0.47 | -0.65 | -1.49 | +142.6% |
| Diluted EPS | 0.19 | -0.47 | -0.65 | -1.49 | +140.3% |
| EBIT | $475.09M | -$511.20M | -$821.47M | -$1.79B | +192.9% |
| EBITDA | $616.77M | -$339.43M | -$733.80M | -$1.72B | +281.7% |
| Basic shares | 1.42B | 1.37B | 1.36B | 1.34B | +3.6% |
| Diluted shares | 1.47B | 1.37B | 1.36B | 1.34B | +7.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $4.55B | $2.63B | $3.17B | $3.87B | +73.1% |
| Cash & short-term investments | $4.55B | $2.63B | $3.17B | $4.53B | +73.1% |
| Accounts receivable | $865.08M | $676.28M | $358.03M | $173.17M | +27.9% |
| Inventory | $608.23M | $494.99M | $416.12M | $282.35M | +22.9% |
| Total current assets | $6.23B | $3.99B | $4.20B | $5.21B | +56.2% |
| Property, plant & equipment | $1.72B | $1.64B | $1.37B | $923.98M | +4.3% |
| Goodwill & intangibles | $141.58M | $129.76M | $108.86M | $94.57M | +9.1% |
| Total assets | $8.19B | $5.92B | $5.81B | $6.38B | +38.3% |
| Total current liabilities | $1.83B | $2.21B | $1.81B | $1.47B | -17.4% |
| Current debt | $57.29M | $851.53M | $688.37M | $328.97M | -93.3% |
| Long-term debt | $961.91M | $166.48M | $197.62M | $209.15M | +477.8% |
| Total debt | $1.09B | $1.08B | $930.18M | $596.67M | +1.2% |
| Total liabilities | $3.83B | $2.59B | $2.27B | $2.00B | +47.9% |
| Retained earnings | -$8.32B | -$8.61B | -$7.96B | -$7.08B | +3.3% |
| Shareholder equity | $4.36B | $3.33B | $3.54B | $4.38B | +30.9% |
| Working capital | $4.40B | $1.78B | $2.39B | $3.74B | +147.9% |
| Net tangible assets | $4.22B | $3.20B | $3.43B | $4.29B | +31.8% |
| Shares issued | 1.54B | 1.38B | 1.35B | 1.36B | +11.3% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $286.93M | -$644.79M | -$881.71M | -$2.00B | +144.5% |
| Depreciation & amortisation | $141.69M | $171.76M | $87.67M | $66.28M | -17.5% |
| Stock-based compensation | $510.86M | $441.62M | $367.62M | $303.16M | +15.7% |
| Change in working capital | $190.90M | -$157.17M | -$370.54M | $132.39M | +221.5% |
| Operating cash flow | $1.13B | -$140.63M | -$1.16B | -$1.50B | +901.8% |
| Capital expenditure | -$266.53M | -$529.14M | -$596.26M | -$469.10M | +49.6% |
| Investing cash flow | -$276.15M | -$548.35M | $60.00M | $1.08B | +49.6% |
| Financing cash flow | $1.06B | $193.45M | $416.48M | -$18.97M | +447.7% |
| Free cash flow | $861.05M | -$669.77M | -$1.75B | -$1.97B | +228.6% |
| End cash position | $4.61B | $2.64B | $3.19B | $3.88B | +74.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $1.71B | $1.51B | $1.50B | $1.41B | $1.32B | — | +12.7% |
| Operating revenue | $2.23B | $1.89B | $1.96B | $1.77B | $1.67B | — | +17.7% |
| Cost of revenue | $174.53M | $167.22M | $142.42M | $196.51M | $164.61M | — | +4.4% |
| Gross profit | $1.53B | $1.35B | $1.36B | $1.22B | $1.15B | — | +13.7% |
| Research & development | $612.28M | $541.22M | $615.42M | $523.66M | $524.90M | — | +13.1% |
| Selling, general & admin | $593.21M | $555.10M | $555.29M | $529.00M | $537.91M | — | +6.9% |
| Total operating expense | $1.21B | $1.10B | $1.17B | $1.05B | $1.06B | — | +10.0% |
| Operating income | $325.05M | $249.90M | $185.03M | $163.11M | $87.89M | — | +30.1% |
| Net interest income | -$11.84M | -$5.22M | -$103.00K | $3.03M | $3.50M | — | -126.7% |
| Pre-tax income | $312.46M | $259.21M | $149.24M | $147.16M | $99.55M | — | +20.5% |
| Tax provision | $75.45M | $31.86M | $82.74M | $22.32M | $5.23M | — | +136.8% |
| Net income | $237.01M | $227.36M | $66.50M | $124.84M | $94.32M | — | +4.2% |
| Net income to common | $237.01M | $227.36M | $66.50M | $124.84M | $94.32M | — | +4.2% |
| Basic EPS | 0.16 | 0.16 | 0.05 | — | 0.07 | 0.00 | 0.0% |
| Diluted EPS | 0.16 | 0.15 | 0.04 | — | 0.06 | 0.00 | +6.7% |
| EBIT | $352.20M | $292.10M | $212.99M | $163.11M | $107.54M | — | +20.6% |
| EBITDA | $392.71M | $333.25M | $248.97M | $200.40M | $143.16M | — | +17.8% |
| Basic shares | 1.45B | 1.44B | 1.44B | — | 1.41B | 1.39B | +0.6% |
| Diluted shares | 1.51B | 1.51B | 1.50B | — | 1.46B | 1.45B | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.10B | $4.79B | $4.55B | $4.04B | $2.76B | +6.4% |
| Cash & short-term investments | $5.10B | $4.79B | $4.55B | $4.04B | $2.76B | +6.4% |
| Accounts receivable | $1.06B | $938.02M | $865.08M | $863.28M | $770.78M | +12.6% |
| Inventory | $732.60M | $681.59M | $608.23M | $531.69M | $502.87M | +7.5% |
| Total current assets | $7.22B | $6.60B | $6.23B | $5.66B | $4.31B | +9.3% |
| Property, plant & equipment | $1.79B | $1.79B | $1.72B | $1.77B | $1.77B | +0.3% |
| Goodwill & intangibles | $60.96M | $61.68M | $141.58M | $63.58M | $64.89M | -1.2% |
| Total assets | $9.18B | $8.55B | $8.19B | $7.63B | $6.30B | +7.3% |
| Total current liabilities | $2.12B | $1.81B | $1.83B | $2.37B | $2.21B | +17.0% |
| Current debt | $190.90M | $116.14M | $57.29M | $813.30M | $808.39M | +64.4% |
| Long-term debt | $882.16M | $962.51M | $961.91M | $139.57M | $146.09M | -8.3% |
| Total debt | $1.14B | $1.15B | $1.09B | $1.02B | $1.03B | -0.5% |
| Total liabilities | $4.00B | $3.79B | $3.83B | $3.50B | $2.53B | +5.5% |
| Retained earnings | -$7.86B | -$8.09B | -$8.32B | -$8.39B | -$8.51B | +2.9% |
| Shareholder equity | $5.17B | $4.76B | $4.36B | $4.13B | $3.77B | +8.7% |
| Working capital | $5.10B | $4.79B | $4.40B | $3.30B | $2.10B | +6.4% |
| Net tangible assets | $5.11B | $4.70B | $4.22B | $4.07B | $3.71B | +8.8% |
| Shares issued | 1.47B | 1.54B | 1.54B | 1.54B | 1.54B | -4.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $237.01M | $227.36M | $66.50M | $124.84M | $94.32M | +4.2% |
| Depreciation & amortisation | $40.52M | $41.14M | $35.98M | $37.28M | $35.61M | -1.5% |
| Stock-based compensation | $137.41M | $123.36M | $123.76M | $140.81M | $150.81M | +11.4% |
| Change in working capital | $69.75M | -$189.14M | $163.55M | $100.02M | $5.35M | +136.9% |
| Operating cash flow | $462.82M | $201.34M | $417.35M | $402.55M | $263.60M | +129.9% |
| Capital expenditure | -$47.99M | -$40.79M | -$37.52M | -$48.77M | -$63.83M | -17.7% |
| Investing cash flow | -$49.35M | -$45.51M | -$38.34M | -$49.27M | -$66.61M | -8.4% |
| Financing cash flow | -$6.05M | $68.63M | $96.93M | $961.27M | $35.02M | -108.8% |
| Free cash flow | $414.83M | $160.55M | $379.82M | $353.78M | $199.77M | +158.4% |
| End cash position | $5.28B | $4.85B | $4.61B | $4.11B | $2.79B | +8.8% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $1.75B | +24.3% |
| Next quarter | — | — | $1.79B | +19.2% |
| Current year | — | — | $6.77B | +26.7% |
| Next year | — | — | $7.78B | +14.9% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders13.75%
Held by institutions28.71%
Institutions holding351
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
21.95
+0.00% from price
SMA 20
21.95
0.00% from price
SMA 50
21.95
0.00% from price
SMA 100
22.04
-0.43% from price
SMA 200
23.11
-5.04% from price
EMA 12
21.95
+0.00% from price
EMA 26
21.95
-0.00% from price
EMA 50
21.98
-0.14% from price
RSI (14)
0.0
Oversold
MACD (12,26,9)
-0.00
Hist 0.00
ATR (14)
0.00
—
Realised vol 30D
0.0%
Annualised
Bollinger upper
21.95
20, 2σ
Bollinger lower
21.95
20, 2σ
50 / 200 cross
Death
21.95 vs 23.11
Trend bias
Below 200
-5.04%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.08
Less volatile than market
Correlation to SPY
0.02
Largely independent
Realised vol 30D
0.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-13.2%
Peak to trough
Max drawdown 5Y
-34.4%
Peak to trough
ATR 14
0.00
Average true range
Beta (reported)
0.61
5Y monthly, from filing
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
Headlines
Biotech Leader BeOne Medicines Poised To Hit Early Buy Points
Investor's Business Daily · 6d ago
BeOne Medicines (ONC) Stock May Be Fully Priced After An 86% Run
Simply Wall St. · 32d ago
The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal
Simply Wall St. · 33d ago
BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It?
Insider Monkey · 33d ago
FDA Approval Marks A Turning Point For BeOne Medicines (ONC)
Insider Monkey · 36d ago
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
Zacks · 36d ago
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
Business Wire · 36d ago
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
Business Wire · 37d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.